Traders purchased shares of Abbott Laboratories (NYSE:ABT) on weakness during trading hours on Monday. $49.00 million flowed into the stock on the tick-up and $38.90 million flowed out of the stock on the tick-down, for a money net flow of $10.10 million into the stock. Of all equities tracked, Abbott Laboratories had the 21st highest net in-flow for the day. Abbott Laboratories traded down ($0.21) for the day and closed at $42.09

ABT has been the topic of several recent research reports. Barclays PLC reiterated an “overweight” rating and set a $48.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, July 12th. Bank of America Corp. reiterated a “buy” rating and set a $50.00 price objective on shares of Abbott Laboratories in a research report on Friday, August 12th. TheStreet upgraded Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, August 22nd. Credit Suisse Group AG restated a “buy” rating on shares of Abbott Laboratories in a research report on Wednesday, June 8th. Finally, Jefferies Group raised their price target on Abbott Laboratories from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, August 4th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Abbott Laboratories currently has a consensus rating of “Buy” and an average price target of $47.08.

The company has a 50-day moving average price of $43.83 and a 200-day moving average price of $40.92. The company has a market cap of $61.87 billion and a P/E ratio of 27.78.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, July 20th. The healthcare product maker reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.53 by $0.02. During the same period last year, the company posted $0.52 EPS. The company had revenue of $5.30 billion for the quarter, compared to analysts’ expectations of $5.24 billion. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, equities research analysts predict that Abbott Laboratories will post $2.20 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, August 15th. Shareholders of record on Friday, July 15th were paid a $0.26 dividend. The ex-dividend date of this dividend was Wednesday, July 13th. This represents a $1.04 dividend on an annualized basis and a yield of 2.47%.

In other Abbott Laboratories news, VP Robert E. Funck sold 26,800 shares of the company’s stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $43.08, for a total value of $1,154,544.00. Following the transaction, the vice president now directly owns 111,819 shares in the company, valued at approximately $4,817,162.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Hubert L. Allen sold 3,400 shares of the company’s stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $37.14, for a total value of $126,276.00. Following the completion of the transaction, the executive vice president now owns 91,857 shares in the company, valued at $3,411,568.98. The disclosure for this sale can be found here.

Other institutional investors have made changes to their positions in the company. Ancora Advisors LLC raised its position in shares of Abbott Laboratories by 11.7% in the fourth quarter. Ancora Advisors LLC now owns 50,506 shares of the healthcare product maker’s stock worth $2,274,000 after buying an additional 5,300 shares in the last quarter. Autus Asset Management LLC raised its position in shares of Abbott Laboratories by 5.4% in the fourth quarter. Autus Asset Management LLC now owns 99,700 shares of the healthcare product maker’s stock worth $4,478,000 after buying an additional 5,126 shares in the last quarter. Investment Management of Virginia LLC raised its position in shares of Abbott Laboratories by 3.8% in the fourth quarter. Investment Management of Virginia LLC now owns 111,116 shares of the healthcare product maker’s stock worth $4,990,000 after buying an additional 4,098 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Abbott Laboratories by 31.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 357,129 shares of the healthcare product maker’s stock worth $16,039,000 after buying an additional 85,800 shares in the last quarter. Finally, United Capital Financial Advisers LLC raised its position in shares of Abbott Laboratories by 2.3% in the fourth quarter. United Capital Financial Advisers LLC now owns 464,033 shares of the healthcare product maker’s stock worth $20,840,000 after buying an additional 10,472 shares in the last quarter.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.